

AMENDMENTS

IN THE CLAIMS:

Please cancel claims 1-18 inclusive.

Please amend the claims as follows:

SUB B1
10058891.01.2802
19. (Amended) A formulation of [Claim 1 containing] sufficient enteric fluoxetine pellets to administer [20-100]60-120 mg base equivalent of fluoxetine, wherein the pellets comprise a core consisting of fluoxetine and one or more pharmaceutically acceptable excipients and an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and one or more pharmaceutically acceptable excipients.

20. (Amended) A formulation of Claim 19 [containing] administering about 80-90 mg base equivalent of fluoxetine.

21. (Amended) A formulation of Claim 19 [containing] administering about 90 mg of base equivalent of fluoxetine.

SUB B1
25. (Amended) A gelatin capsule containing sufficient enteric fluoxetine pellets to administer a dose of 60-120 mg base equivalents of fluoxetine, wherein the pellets comprise a core consisting of fluoxetine and one or more pharmaceutically acceptable excipients and an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and one or more pharmaceutically acceptable excipients [the formulation of Claim 1].

26. (Amended) A gelatin capsule [containing the formulation] of Claim [24]25, wherein about 80-90 base equivalents of fluoxetine are administered.

27. (Amended) A formulation of Claim 19 containing the following:

Cores

Sucrose - starch nonpareils, 30-35 mesh 100-150

mg

Fluoxetine layer

Fluoxetine hydrochloride 100.5-100.8 mg

Sucrose 20-30 mg

Hydroxypropylmethylcellulose 10-15 mg

Separating layer

Hydroxypropylmethylcellulose 4-12 mg

Sucrose 15-35 mg

Talc, 500 mesh 25-60 mg

Enteric layer

HPMCAS-LF 60-90 mg

Triethyl citrate 10-20 mg

Talc, 500 mesh 15-25 mg

Finishing layer

Color mixture white (HPMC + titanium dioxide) 35-55 mg

HPMC 5-15 mg

Talc Trace.

28. (Amended) A gelatin capsule [containing the formulation] of Claim [24]25, wherein about 90 mg base equivalent of fluoxetine are administered.

29. (Amended) A formulation according to Claim 19 wherein the formulation additionally contains pindolol.

30. (Amended) A method of treating [people]a patient suffering from depression, obsessive-compulsive disorder, bulimia, pain, obsessive-compulsive personality disorder, post-traumatic stress disorder, hypertension, atherosclerosis, anxiety, anorexia nervosa, panic, social phobia, stuttering, sleep disorders, chronic fatigue, Alzheimer's disease, alcohol abuse, appetite disorders, weight loss, agoraphobia, improving memory, amnesia, smoking

cessation, nicotine withdrawal syndrome symptoms, disturbances of mood and/or appetite associated with pre-menstrual syndrome, depressed mood and/or carbohydrate craving associated with pre-menstrual syndrome, disturbances of mood, disturbances of appetite or disturbances which contribute to recidivism associated with nicotine withdrawal, circadian rhythm disorder, borderline personality disorder, hypochondriasis, pre-menstrual syndrome (PMS), late luteal phase dysphoric disorder, pre-menstrual dysphoric disorder, trichotillomania, symptoms following discontinuation of other antidepressants, aggressive/intermittent explosive disorder, compulsive gambling, compulsive spending, compulsive sex, psychoactive substance use disorder, sexual disorder, schizophrenia, premature ejaculation, or psychiatric symptoms selected from stress, worry, anger, rejection sensitivity, and lack of mental or physical energy comprising administering a formulation of Claim 19.

31. (Amended) A method of Claim 30 employing a formulation [containing 20-100] administering about 80-90 mg base equivalent of fluoxetine.

32. (Amended) A method of Claim 30 employing a formulation [containing] administering about 90 mg base equivalent of fluoxetine.

37. (Amended) A method of Claim 30 of treating [people] a patient suffering from pain, further comprising the coadministration of morphine, codeine or dextropropoxyphene.

38. (Amended) A method of Claim 37 employing a formulation [containing about 20-100] administering about 80-90 mg base equivalent of fluoxetine.

39. (Amended) A method of Claim 37 employing a formulation [containing] administering about 90 mg base equivalent of fluoxetine.

Please add new claims 40-75.

40. (New) A formulation of Claim 19, wherein the pellets further comprise a separating layer.

41. (New) A formulation of Claim 40, wherein the separating layer comprises a non-reducing sugar and one or more pharmaceutically acceptable excipients.

42. (New) A formulation of Claim 19, wherein the pellets further comprise a finishing layer.

43. (New) A formulation of Claim 40, wherein the pellets further comprise a finishing layer.

44. (New) A formulation of Claim 41, wherein the pellets further comprise a finishing layer.

45. (New) A formulation of Claim 21, wherein the pellets further comprise a separating layer.

46. (New) A formulation of Claim 45, wherein the separating layer comprises a non-reducing sugar and one or more pharmaceutically acceptable excipients.

47. (New) A formulation of Claim 21, wherein the pellets further comprise a finishing layer.

48. (New) A formulation of Claim 45, wherein the pellets further comprise a finishing layer.

49. (New) A formulation of Claim 46, wherein the pellets further comprise a finishing layer.

50. (New) A gelatin capsule of Claim 25, wherein the pellets further comprise a separating layer.

51. (New) A gelatin capsule of Claim 50, wherein the separating layer comprises a non-reducing sugar and one or more pharmaceutically acceptable excipients.

52. (New) A gelatin capsule of Claim 25, wherein the pellets further comprise a finishing layer.

53. (New) A gelatin capsule of Claim 50, wherein the pellets further comprise a finishing layer.

54. (New) A gelatin capsule of Claim 51, wherein the pellets further comprise a finishing layer.

55. (New) A gelatin capsule of Claim 28, wherein the pellets further comprise a separating layer.

56. (New) A gelatin capsule of Claim 55, wherein the separating layer comprises a non-reducing sugar and one or more pharmaceutically acceptable excipients.

57. (New) A gelatin capsule of Claim 28, wherein the pellets further comprise a finishing layer.

58. (New) A gelatin capsule of Claim 55, wherein the pellets further comprise finishing layer.

59. (New) A gelatin capsule of Claim 56, wherein the pellets further comprise a finishing layer.

60. (New) A method of Claim 30, wherein the pellets further comprise a separating layer.

61. (New) A method of Claim 60, wherein the separating layer comprises a non-reducing sugar and one or more pharmaceutically acceptable excipients.

62. (New) A method of Claim 30, wherein the pellets further comprise a finishing layer.

63. (New) A method of Claim 60, wherein the pellets further comprise a finishing layer.

64. (New) A method of Claim 61, wherein the pellets further comprise a finishing layer.

65. (New) A method of Claim 32, wherein the pellets further comprise a separating layer.

66. (New) A method of Claim 65, wherein the separating layer comprises a non-reducing sugar and one or more pharmaceutically acceptable excipients.

67. (New) A method of Claim 32, wherein the pellets further comprise a finishing layer.

68. (New) A method of Claim 65, wherein the pellets further comprise a finishing layer.

69. (New) A method of Claim 66, wherein the pellets further comprise a finishing layer.

70. (New) A method of Claim 30 without an increase in nausea.

71. (New) A method of Claim 32 without an increase in nausea.